^
Association details:
| Biomarker: | PRKCH-SPTB fusion |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | darovasertib (IDE196) (PKC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4152: Preclinical evaluation of PRKC fusions and GNA11/GNAQ mutations as genetic drivers of PKC activation in non-MUM indications to support a phase 1/2 basket trial of IDE196
Published date:
05/15/2020
Excerpt:
...we assessed the sensitivity of non-MUM cell lines that have PRKC gene fusions or GNAQ/11 hotspot/non-hotspot mutations to IDE196....8/10 PRKCH fusion lines were highly resistant to IDE196 (IC50>10μM, including HIF1A-PRKCH and RP11-47I22.3-PRKCH fusion lines), whereas 2/10 showed sensitivity at high doses in the long-term viability assay (IC50≥1μM, lines with PRKCH-SPTB or VWA2-PRKCH fusions).
DOI:
10.1158/1538-7445.AM2020-4152
